Asset Details
Do you wish to reserve the book?
Out of stock: A brief clinical reference for rough equivalency of glucagon‐like peptide‐1 (GLP‐1) ± glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists for A1c and weight reduction in people with type 2 diabetes
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Out of stock: A brief clinical reference for rough equivalency of glucagon‐like peptide‐1 (GLP‐1) ± glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists for A1c and weight reduction in people with type 2 diabetes
Do you wish to request the book?
Out of stock: A brief clinical reference for rough equivalency of glucagon‐like peptide‐1 (GLP‐1) ± glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists for A1c and weight reduction in people with type 2 diabetes
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Out of stock: A brief clinical reference for rough equivalency of glucagon‐like peptide‐1 (GLP‐1) ± glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists for A1c and weight reduction in people with type 2 diabetes
2024
Overview
Highlights
Despite the common practice of switching patients from one medicine to another—to improve efficacy, safety, or tolerability—guidance on how to do so is uncommon. During this time of global shortage of glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) ± glucose‐dependent insulinotropic polypeptide (GIP) RA therapies, this research letter offers a quick clinical reference of rough equivalency between GLP‐1 ± GIP RA for A1c and body weight reduction in people with type 2 diabetes.
Publisher
Wiley Publishing Asia Pty Ltd,John Wiley & Sons, Inc,Wiley
Subject
/ Diabetes
/ Diabetes Mellitus, Type 2 - blood
/ Diabetes Mellitus, Type 2 - drug therapy
/ GLP‐1
/ Glucagon-Like Peptide 1 - agonists
/ Glycated Hemoglobin - analysis
/ Glycated Hemoglobin - metabolism
/ Humans
/ Hypoglycemic Agents - therapeutic use
